Drug Profile
ApoB SNALP
Alternative Names: PRO-040201; TKM-ApoBLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Tekmira Pharmaceuticals Corporation
- Developer Arbutus Biopharma
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action Apolipoprotein B inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercholesterolaemia